Microsoft word - prog_feb2006_4_pdf.doc

Stapleford-Berlin 2006
Latest developments in effective medical treatments for addiction.
The 3rd Berlin Stapleford International Addiction Conference.
Berlin. Weekend of March 18-20th 2006.
Some timing and other details may still be subject to change. Poster presentations will be on display throughout the conference and it is hoped that those wanting more
information will easily be able to approach the authors at any time, as well as during lunch and coffee breaks.
Authors may like to pin a passport-size photograph of themselves on their posters to assist recognition.

Saturday 18th March 2006:
ALTERNATIVES TO ORAL METHADONE OR BUPRENORPHINE FOR AGONIST MAINTENANCE;
DEPOT BUPRENORPHINE AND SLOW-RELEASE MORPHINE.


08.30 Welcome and introduction: Linda Partecke, Colin Brewer.
Transfering from high doses of methadone to buprenorphine: A randomised trial of three different buprenorphine schedules. Influence of psychiatric comorbidity on additional abuse of drugs in maintenance treatment with l- and d/l-methadone Development of the peripheral opiate antagonist methylnaltrexone: potential uses in addiction treatment. 10.15 Coffee break
DEPOT AND IMPLANTED NALTREXONE
10.30 Chair and introduction: Prof. Mats Berglund.
Clinical trials of depot naltrexone in opiate abusers. Vivitrol: Development, effectiveness and prospects. From Volpicelli to Vivitrol: Clinical use of long-acting naltrexone in alcoholism: a review A ‘bio-relevant’ approach to drug-release: testing of a biodegradable naltrexone implant Naltrexone as anticraving treatment: a psychophysiological evaluation. Does naltrexone influence craving in opioid-dependent patients after detoxification? Stable elevations in striatal µ-opioid receptor availability in detoxified alcoholics correlate with alcohol craving: A [11C]Carfentanil PET study. Tissue compatibility, biodegradability, blood naltrexone levels, and heroin overdose following treatment of heroin dependent persons with sustained release naltrexone-poly(dl-lactide) implants. Tissue tolerance and pharmacokinetics of Berlin subcutaneous naltrexone implants. New treatments, new challenges. Persistent heroin use despite naltrexone implantation. The problem of intravenous buprenorphine injection with naltrexone implants. Maintenance treatment with oral naltrexone for opioid dependence: a systematic review and meta-analysis A comparison of oral and implanted naltrexone in heroin addiction: outcomes at 12 months. An audited two-year comparison of 12-month O’Neil naltrexone implantation with supervised methadone maintenance in general practice. A matched case-control study of naltrexone implants for relapse prevention in detoxified opioid addicts. A review of mortality of patients entering a naltrexone implant treatment programme over a five-year period. Negative correlation between the availability of state-funded (NHS) naltrexone implants and shop theft rates in Bradford, September 2002–March 2005: a natural experiment. How should psychotherapy and counselling evolve in the implant age?
Sunday 19th March:
RAPID NALTREXONE INDUCTION TECHNIQUES;
anaesthesia, oral sedation or something in-between?

09.00 Chair and introduction: Prof. Gabrielle Fischer
The Columbia study: oral sedation after 24hr buprenorphine stabilisation is equally effective and safer than anaesthesia. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment. Rapid opioid detoxification under general anaesthesia: does the benefit of general anaesthesia outweigh the risk? Intravenous sedation is a reasonable compromise. Out-patient detox services: experience with over 8000 procedures using light i/v sedation. Evolution of techniques over 10 years and 10,000 patients. Rapid opiate detoxification precipitated by subcutaneous naltrexone pellet implantation using ketamine anaesthesia. Newer strategies in de-addiction: an Indian perspective Differential pharmacological treatments of addiction: methodological implications. Subjective sleep and restless legs before, during and after opiate withdrawal. 12.25 Round table. Where do we go from here? Written questions will be invited. 13.00 Lunch
DISULFIRAM vs NALTREXONE AND ACAMPROSATE IN ALCOHOLISM.
14.00 Chair and introduction: Jonathan Chick, Edinburgh.
Results of the Helsinki randomised trial of disulfiram, naltrexone and acamprosate. Studies of family-supervised disulfiram, naltrexone and acamprosate in an Indian setting. High effectiveness of long-term disulfiram in a structured out-patient rehabilitation programme. An effective disulfiram implant - but is this the way forward? 15.40 Tea break
RAPID BENZODIAZEPINE DETOXIFICATION WITH FLUMAZENIL.
16.00 Chair and introduction: Catherine de Jong.
Experience with 200 in-patients: safe and effective even from high benzodiazepine doses. Rapid benzodiazepine withdrawal as an out-patient procedure. Development and prospects of flumazenil implants.
Monday 20th March:
09.00 to 12.00 WORKSHOP ON RAPID OPIATE/BENZO DETOX AND IMPLANTS

Dr. Linda Partecke and Dr. Colin Brewer, 19 Feb. 2006

Source: http://www.stapleford-berlin2006.de/prog_add_conf_2006.pdf